Bosutinib, a Lyn/Btk inhibiting tyrosine kinase inhibitor, is ineffective in advanced systemic mastocytosis

American Journal of Hematology

Volumn 90, Issue 4, 2015, Pages E74-E74

  Randall, Nicole ^a   Courville, Elizabeth L ^b   Baughn, Linda ^b   Afrin, Lawrence ^a   Ustun, Celalettin ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIHISTAMINIC AGENT; BOSUTINIB; CD2 ANTIGEN; CLADRIBINE; INTERLEUKIN 2 RECEPTOR ALPHA; STEM CELL FACTOR RECEPTOR; TRYPTASE; ANILINE DERIVATIVE; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; NITRILE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; QUINOLINE DERIVATIVE;

ADULT; ADVANCED SYSTEMIC MASTOCYTOSIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; DISEASE EXACERBATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; GENE MUTATION; HEPATOSPLENOMEGALY; HUMAN; HUMAN CELL; MALE; MAST CELL; MIDDLE AGED; MYELOFIBROSIS; OSTEOSCLEROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIDE EFFECT; SPINDLE CELL; SYSTEMIC MASTOCYTOSIS; THROMBOCYTE COUNT; URTICARIA PIGMENTOSA; CONGENITAL TUMOR; FEMALE; GENETICS; METABOLISM;

ANILINE COMPOUNDS; ANTINEOPLASTIC AGENTS; BENZAMIDES; FEMALE; HAMARTOMA SYNDROME, MULTIPLE; HUMANS; MALE; MAST CELLS; MASTOCYTOSIS, SYSTEMIC; NITRILES; PIPERAZINES; PTEN PHOSPHOHYDROLASE; PYRIMIDINES; QUINOLINES;

EID: 84925354373     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23942     Document Type: Article

References (6)

1. Tantravahi SK, Schumacher J, Burt RW, et al. Systemic mastocytosis in a patient with cowden syndrome. Am J Hematol 2014;89:1154.
2. Gambacorti-Passerini C, Cortes JE, Lipton JH, et al. Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. Am J Hematol 2014;89:947-953.
3. Lim KH, Tefferi A, Lasho TL, et al. Systemic mastocytosis in 342 consecutive adults: Survival studies and prognostic factors. Blood 2009;113:5727-5736.
4. Ustun C, Corless CL, Savage N, et al. Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V. Leuk Res 2009;33:735-741.
5. Ustun C, DeRemer DL, Akin C. Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. Leuk Res 2011;35:1143-1152.
6. Gleixner KV, Mayerhofer M, Cerny-Reiterer S, et al. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: Role of Lyn and Btk activation and disruption by dasatinib and bosutinib. Blood 2011;118:1885-1898.